Most Read Articles
Audrey Abella, 09 Jun 2017
Maintenance therapy with olaparib significantly improved progression-free survival (PFS) and patient-centred benefits in patients with germline BRCA-mutated, platinum-sensitive relapsed serous ovarian cancer (gBRCAm PSR SOC) compared with placebo, according to the SOLO* 2 trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.
Elvira Manzano, 14 Jun 2017
The oral PARP inhibitor olaparib significantly improved progression-free survival (PFS) in women with BRCA-positive, HER2-negative breast cancer compared with standard chemotherapy in the phase III OlympiAD* trial, ushering in a new era of hope in BRCA-mutated breast cancer.
Pearl Toh, 01 Aug 2016
Understanding biomarkers predictive of treatment outcomes or response can help inform treatment decisions and personalize care for advanced prostate cancer patients, suggested an expert at the recent Urological Association of Asia Annual Congress (UAA 2016) held in Singapore.
Audrey Abella, 13 Jun 2017
A psychological intervention, Conquer Fear, may help alleviate fear of cancer recurrence (FCR) in cancer survivors, according to a study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.

Infections predict death in diffuse large B cell lymphoma

16 Jul 2017
GIS, CSI make first collaborative discovery on cancer progression

Diffuse large B cell lymphoma (DLBCL) patients with neutropenia and multiple comorbidities have a high risk of death and infection, a new study reports. Moreover, infection is an independent predictor of survival.

In a cohort of 325 DLBCL patients, Charlson Comorbidity Index (CCI) scores of 3 to 5 (hazard ratio [HR], 2.16; 95 percent CI, 1.71 to 2.74; p<0.001) and ≥6 (HR, 3.91; 2.34 to 6.28; p<0.001) were significantly correlated with infections.

Having Eastern Cooperative Oncology Group (ECOG) scores of 1 (HR, 2.09; 1.46 to 3.01; p<0.001), 2 (HR, 3.33; 2.22 to 5.04; p<0.001) and 3 (HR, 3.36; 1.99 to 5.66; p<0.001), and neutropenia within 48 hours (HR, 2.46; 1.91 to 3.17; p<0.001) were also associated with increased risks of infection.

Over the study duration of 10 years, 99 deaths (30.5 percent) were reported. The median time from diagnosis to death was 273 (129 to 636) days. The most common cause of death was progressive lymphoma (58.6 percent), followed by infection (12.1 percent) and other cancers (5.5 percent).

CCI scores of 3 to 5 (HR, 4.34; 2.00 to 6.33; p<0.001) and ≥6 (HR, 7.36; 3.38 to 16.00; p<0.001), an ECOG status of 1 (HR, 2.61; 1.02 to 6.66; p=0.045) and 3 or 4 (HR, 7.16; 2.04to 25.06; p=0.002), and infection upon admission (HR, 3.27; 2.03 to 5.27; p<0.001) were all independent and significant predictors of survival.

Participants were recruited from Monash Health I Melbourne, Australia, and were receiving rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) or similar chemotherapies.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Audrey Abella, 09 Jun 2017
Maintenance therapy with olaparib significantly improved progression-free survival (PFS) and patient-centred benefits in patients with germline BRCA-mutated, platinum-sensitive relapsed serous ovarian cancer (gBRCAm PSR SOC) compared with placebo, according to the SOLO* 2 trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.
Elvira Manzano, 14 Jun 2017
The oral PARP inhibitor olaparib significantly improved progression-free survival (PFS) in women with BRCA-positive, HER2-negative breast cancer compared with standard chemotherapy in the phase III OlympiAD* trial, ushering in a new era of hope in BRCA-mutated breast cancer.
Pearl Toh, 01 Aug 2016
Understanding biomarkers predictive of treatment outcomes or response can help inform treatment decisions and personalize care for advanced prostate cancer patients, suggested an expert at the recent Urological Association of Asia Annual Congress (UAA 2016) held in Singapore.
Audrey Abella, 13 Jun 2017
A psychological intervention, Conquer Fear, may help alleviate fear of cancer recurrence (FCR) in cancer survivors, according to a study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.